578 results on '"TORTORA, GIAMPAOLO"'
Search Results
2. Benefit of a multimodal approach combining chemotherapy and surgery in oligometastatic gastric cancer: experience from a tertiary referral center
3. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW.
4. A pituitary metastasis from occult neuroendocrine carcinoma
5. MP53-07 EFFICACY AND SAFETY OF THE COMBINATION OF CISPLATIN PLUS NAB-PACLITAXEL AND NIVOLUMAB WITH RADIOTHERAPY AFTER MAXIMAL TUMOR RESECTION IN NON-METASTATIC MUSCLE INVASIVE BLADDER CANCER (CNN-BC TRIAL)
6. Quality of life impact in patients with cutaneous toxicities caused by EGFR inhibitors and immunotherapy
7. Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
8. Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms
9. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced nonsmall cell lung cancer
10. Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
11. Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives
12. Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis
13. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
14. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer
15. The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)—What Future Prospects Are There for Its Use in Clinical Practice?
16. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
17. Second-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective experience.
18. Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives
19. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer
20. Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study
21. Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
22. THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
23. Surgery for locally advanced gastric cancer in the era of neoadjuvant therapies: something new?
24. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes
25. Evolutionary fingerprints of EMT in pancreatic cancers
26. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
27. Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)
28. Maintenance Strategies After Anti-EGFR-based Induction in Metastatic Colorectal Cancer: A Systematic Review and Bayesian Network Meta-analysis
29. A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors
30. Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications
31. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
32. KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors
33. Unexpected finding of a rare pathogenic germline BRCA1 variant in an intrahepatic cholangiocarcinoma using the Oncomine Focus DNA assay: clinical and diagnostic implications
34. Somatostatin Analogues or Active Surveillance in Sporadic and MEN1 associated Non-functioning Pancreatic Neuroendocrine Tumors
35. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic insulinoma: A single-center experience
36. A digital solution to support the Multidisciplinary Tumor Board activities: implementation process and impact analysis
37. Identification of novel spatially resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms
38. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
39. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario
40. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
41. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
42. Supplementary Figure 3 from Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
43. Supplementary Figures from Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
44. Table S2 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
45. Supplementary methods from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
46. Table S3 from Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
47. Supplementary Table S1 from Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
48. Supplementary Table S3 from Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
49. Supplementary Figures from Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
50. Data from Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.